Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

On March 20, 2025, Alnylam received approval from the U.S. Food and Drug Administration (FDA) for Amvuttra to treat ATTR-CM. The approval came with a broad label that includes language about ...

Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 ...